Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study - PubMed (original) (raw)
Clinical Trial
. 2001 Feb;12(2):218-225.
doi: 10.1681/ASN.V122218.
Affiliations
- PMID: 11158211
- DOI: 10.1681/ASN.V122218
Clinical Trial
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study
Luis M Ruilope et al. J Am Soc Nephrol. 2001 Feb.
Abstract
This article reports further analyses of the Hypertension Optimal Treatment (HOT) Study data with the aim to describe (1) the value of baseline serum creatinine and its clearance (estimated by Cockroft and Gault formula) as predictors of cardiovascular events, (2) the effects of intensive lowering of BP on cardiovascular events and renal function in patients with reduced renal function, and (3) the effects on cardiovascular events of adding acetylsalicylic acid to antihypertensive therapy in patients with reduced renal function. The results show that (1) baseline elevation in serum creatinine and a reduction in estimated creatinine clearance are powerful predictors of cardiovascular events and death. (2) Reduced renal function at baseline did not preclude the desired control of BP. In contrast to patients with normal renal function, the incidence of major cardiovascular events did not differ in the three groups of patients with mild renal insufficiency randomized to different diastolic BP targets. No significant changes in serum creatinine were seen at the end of the 3.8-yr treatment period in the great majority of patients. However, there was a small group of patients (0.58% of the total study population) whose renal function deteriorated (increase > or =30% over baseline and final serum creatinine concentration > or =2 mg/dl) despite satisfactory reduction of diastolic BP. (3) The results of this reanalysis of the HOT Study suggest though do not prove that the association of acetylsalicylic acid with intensive antihypertensive therapy offers additional benefit in hypertensive patients with reduced renal function.
Similar articles
- Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
Voyaki SM, Staessen JA, Thijs L, Wang JG, Efstratopoulos AD, Birkenhäger WH, de Leeuw PW, Leonetti G, Nachev C, Rodicio JL, Tuomilehto J, Fagard R; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Voyaki SM, et al. J Hypertens. 2001 Mar;19(3):511-9. doi: 10.1097/00004872-200103000-00020. J Hypertens. 2001. PMID: 11288822 Clinical Trial. - Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.
Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, Warnold I, Wedel H. Zanchetti A, et al. J Hypertens. 2002 May;20(5):1015-22. doi: 10.1097/00004872-200205000-00038. J Hypertens. 2002. PMID: 12011664 Clinical Trial. - [Effect of arterial pressure and age on renal function, The "Care for the Kidney" study].
Olivares J, Guillén F, Sánchez JJ, Morales-Olivas FJ. Olivares J, et al. Nefrologia. 2003;23(2):137-44. Nefrologia. 2003. PMID: 12778878 Spanish. - Renal protection in hypertensive patients: selection of antihypertensive therapy.
Wenzel RR. Wenzel RR. Drugs. 2005;65 Suppl 2:29-39. doi: 10.2165/00003495-200565002-00005. Drugs. 2005. PMID: 16398060 Review.
Cited by
- The Relationship Between Changes of Left Heart Structure and Function and the Risk of Future Renal Damage in Patients with Essential Hypertension.
Li F, Yan F, Liu S, Baheti R, Feng Y, Wan J. Li F, et al. Int J Gen Med. 2024 May 27;17:2475-2487. doi: 10.2147/IJGM.S459009. eCollection 2024. Int J Gen Med. 2024. PMID: 38826509 Free PMC article. - A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids.
Sabbour H, Bhatt DL, Elhenawi Y, Aljaberi A, Bennani L, Fiad T, Hasan K, Hashmani S, Hijazi RA, Khan Z, Shantouf R. Sabbour H, et al. Cardiovasc Drugs Ther. 2024 Feb 16. doi: 10.1007/s10557-023-07519-z. Online ahead of print. Cardiovasc Drugs Ther. 2024. PMID: 38363478 Review. - Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality-A Comprehensive Review.
Piccirillo F, Liporace P, Nusca A, Nafisio V, Corlianò A, Magarò F, Antonelli Incalzi R, Ussia GP, Grigioni F. Piccirillo F, et al. J Cardiovasc Dev Dis. 2023 May 28;10(6):236. doi: 10.3390/jcdd10060236. J Cardiovasc Dev Dis. 2023. PMID: 37367401 Free PMC article. Review. - Antiplatelet agents for chronic kidney disease.
Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Natale P, et al. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4. Cochrane Database Syst Rev. 2022. PMID: 35224730 Free PMC article. Review. - Hazardous Effect of Low-Dose Aspirin in Patients with Predialysis Advanced Chronic Kidney Disease Assessed by Machine Learning Method Feature Selection.
Tsai MH, Liou HH, Huang YC, Lee TS, Chen M, Fang YW. Tsai MH, et al. Healthcare (Basel). 2021 Oct 31;9(11):1484. doi: 10.3390/healthcare9111484. Healthcare (Basel). 2021. PMID: 34828530 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical